Impact BioMedical Inc. (IBO) stock

IBONYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30

$3.06+0.38 (+14.18%)

Close on Oct 19, 2026Market cap $26.14MP/E –Yield –

Impact BioMedical gross margin

Gross margin is gross profit as a percentage of revenue.

Impact BioMedical's gross margin for the twelve months ending Dec 31, 2025 was -1225.0%. For fiscal 2025 it was -1225.0%.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-1225.0%	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	71.4%	−14.3
Q2 FY2026	Jun 30, 2026	66.7%	–
Q4 FY2025	Dec 31, 2025	-5928.6%	–
Q3 FY2025	Sep 30, 2025	94.4%	–
Q2 FY2025	Jun 30, 2025	85.7%	–

Parsed from the XBRL in Impact BioMedical's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12.67 reverse split on Nov 9, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IBO.

Advertisement
300 × 250

See a number that looks wrong?